ex_630334.htm
Exhibit 99.1
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023
Q3 2024 adjusted EBITDA1 improved by $7.0 million compared to Q3 2023
TTM March 2024 operating income of $7.3 million for the Rx Business
TTM March 2024 companywide adjusted EBITDA of positive $15.4 million
TTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business
$19.8 million cash balance at March 31, 2024
Company to host conference call and webcast today, May 15, 2024, at 4:30 p.m. Eastern time
DENVER, CO / May 15, 2024 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter.
Q3 2024 Highlights
| |
●
|
Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment.
|
| |
●
|
ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 49% to $12.3 million versus $8.3 million in Q3 fiscal 2023.
|
| |
●
|
Consumer Health Segment net revenue during Q3 2024 was $4.0 million, a decrease of 56% versus Q3 2023, in line with the Company's strategy to discontinue the Consumer Health segment in mid-calendar 2024. As previously announced, the Company is ending its Consumer Health Segment’s operations with the objective of driving profitability and generating long-term stockholder value.
|
| |
●
|
Rx Segment gross margin improved to 74% in Q3 2024 compared to 61% in Q3 2023.
|
| |
●
|
Net loss during Q3 2024 was $2.9 million, or $0.52 per share, compared to a net loss of $7.2 million, or $1.93 per share, in Q3 2023.
|
| |
●
|
Consolidated adjusted EBITDA was positive $0.4 million in Q3 2024 compared to negative $6.6 million in Q3 2023.
|
| |
●
|
Cash and cash equivalents were $19.8 million at March 31, 2023, compared to $19.5 million at December 31, 2023.
|
Management Discussion
“The positive operating momentum we have experienced over the past two years continued during the third quarter of fiscal 2024, as ADHD Portfolio revenue continued its rapid growth, increasing 49%, and we improved our adjusted EBITDA by $7.0 million, compared to the year ago third quarter. This represents the first March quarter in the company’s history during which Aytu generated positive adjusted EBITDA, which is notable considering the March quarter is typically our lowest revenue quarter for the Rx Segment due largely to patients’ insurance deductible resets. Further, when considering both the current softness of our pediatric product sales coupled with the well-publicized cyberattack that impacted the entire healthcare industry, we are very encouraged by the Rx Segment’s demonstrated, year over year revenue growth.” commented Josh Disbrow, Chief Executive Officer of Aytu. “Our business is better positioned today than at any point in our history. Aytu generated TTM adjusted EBITDA of $15.4 million, while our balance sheet remains strong with $19.8 million of cash at the end of March 2024.”
“The key drivers to achieving these critical milestones of positive $15.4 million in TTM companywide adjusted EBITDA and positive $17.1 million in Rx Business TTM adjusted EBITDA, have been a combination of redefining our corporate strategic mandate to focus our business solely on the Rx Segment while instituting a number of operational improvements. These improvements include strong sales force execution, the leveraging of our innovative Aytu RxConnect platform, and continued effective expense management. Additionally, once we have fully transitioned manufacturing of our ADHD brands out of our Grand Prairie, Texas facility, we expect to gain additional expense and margin improvements beyond what we’re currently generating. While there is still work to be done to mitigate the negative impact of the payor changes within our Pediatric Portfolio, which we believe we will be successful in addressing, we are excited about the overall trajectory of the business as we finish fiscal 2024,” Mr. Disbrow concluded.
Non-Core Business Update
In June 2023, the Company announced that it had instituted a strategic mandate focusing its business solely on its Rx Segment, in an effort to drive long-term stockholder value. The Company has generated positive adjusted EBITDA for fiscal 2023 and for seven of the last reported eight quarters for Rx, excluding the Consumer Health Segment and pipeline R&D (the “Rx Business”). This concentration on the Rx Segment will result in discontinuing the Consumer Health Segment altogether.
This goal of emphasizing profitability was initially started with the indefinite suspension of all pipeline clinical development programs announced in October 2022 to minimize research and development expense until such time that the Company can fund those efforts with internally generated cash flows or through partnerships. During fiscal 2023, the Consumer Health Segment contributed adjusted EBITDA of negative $3.6 million and pipeline programs contributed adjusted EBITDA of negative $2.6 million, while the Company's Rx Business contributed adjusted EBITDA of positive $9.7 million. Over the Trailing Twelve-Month (“TTM”) period ending March 31, 2024, the Company’s Rx Business contributed operating income of $7.3 million and adjusted EBITDA of positive $17.1 million.
Segment Reporting
|
|
|
Three Months Ended
|
|
|
|
|
March 31,
|
|
|
|
|
2024
|
|
|
2023
|
|
|
|
|
(in thousands)
|
|
|
Consolidated net revenue:
|
|
|
|
|
|
|
|
Rx Segment
|
|
$ |
14,025 |
|
|
$ |
13,805 |
|
|
Consumer Health Segment
|
|
|
3,968 |
|
|
|
8,928 |
|
|
Total consolidated net revenue
|
|
$ |
17,993 |
|
|
$ |
22,733 |
|
|
|
|
|
|
|
|
|
|
Rx Segment net revenue:
|
|
|
|
|
|
|
|
ADHD Portfolio
|
|
$ |
12,326 |
|
|
$ |
8,272 |
|
|
Pediatric Portfolio
|
|
|
1,729 |
|
|
|
5,266 |
|
|
Other*
|
|
|
(30 |
) |
|
|
267 |
|
|
Total Rx Segment net revenue
|
|
$ |
14,025 |
|
|
$ |
13,805 |
|
*Other includes discontinued or deprioritized products.
Q3 2024 Financial Results
Net revenue for the third quarter of fiscal 2024 was $18.0 million, compared to $22.7 million for the prior year period.
Net revenue from the Rx Segment in the third quarter of fiscal 2024 was $14.0 million compared to $13.8 million in the prior year period. The ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) experienced a 49% increase in net revenue to $12.3 million in the third quarter of fiscal 2024, compared to the prior year period. The Pediatric Portfolio (Poly-Vi-Flor®, Tri-Vi-Flor®, and Karbinal® ER) net revenue decreased to $1.7 million due to customer ordering timing as a result of payor changes that impacted scripts.
Net revenue from the Consumer Health Segment was $4.0 million in the third quarter of fiscal 2024, a decrease of 56% over the same quarter last year. As previously announced, the Company is winding down its Consumer Health Segment with the objective of discontinuing this segment to improve operating cash flows to drive long-term stockholder value.
Consolidated gross profit was $11.7 million, or 65% of net revenue, in the third quarter of fiscal 2024, compared to $12.7 million, or 56% of net revenue, in the same quarter last year. Gross profit margin for the Rx Segment was 74% in the third quarter of fiscal 2024, compared with 61% in the prior year period.
Operating expenses, excluding amortization of intangible assets, restructurings costs, and gain from contingent consideration, were $12.6 million in the third quarter of fiscal 2024 compared to $20.8 million in the prior year period. The decrease was a result of reduced Consumer Health spending and improved operational efficiencies.
Loss from operations during the third quarter of fiscal 2024 was $2.5 million compared to $8.6 million in the prior year period.
Net loss during the third quarter of fiscal 2024 was $2.9 million, or $0.52 per share, compared to a $7.2 million net loss, or $1.93 per share, in the prior year period. The fiscal 2024 third quarter results were impacted by $0.2
million of costs associated with the previously announced winding down of the manufacturing facility.
Adjusted EBITDA was positive $0.4 million in the third quarter of fiscal 2024, compared to negative $6.5 million in the prior year period, a $7.0 million improvement. Adjusted EBITDA for the Rx Business was positive $0.9 million in the third quarter of fiscal 2024, compared to negative $4.7 million in the prior year period, a $5.6 million improvement.
Cash and cash equivalents at March 31, 2023, were $19.8 million compared to $19.5 million at December 31, 2023.
Conference Call Details
Date and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 300411.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/50379, and accessible on the Investors section of the Company’s website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until May 29, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 50379.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company's plans relating to the Company's ability to efficiently wind down the Consumer Health Segment, the Company's ability to complete the manufacturing transfer of Adzenys XR-ODT® and Cotempla XR-ODT®, the Company's overall financial and operational performance, potential adverse changes to the Company's financial position or our business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of our products, our partners performing their required activities, our anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. We also refer you to (i) the risks described in “Risk Factors” in Part I, Item 1A of our most recent Annual Report on Form 10‑K and in the other reports and documents it files with the Securities and Exchange Commission.
Footnote 1
Aytu uses the term adjusted EBITDA, which is a term not defined under United States generally accepted accounting principles (“U.S. GAAP”). The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting adjusted EBITDA by certain categories allows investors to evaluate the various performance of these categories. The Company's method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. We believe that net income (loss) is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to adjusted EBITDA. See below for a reconciliation of net income (loss) to adjusted EBITDA.
Contacts for Investors
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
Aytu BioPharma, Inc.
Unaudited Consolidated Statements of Operations
(in thousands, except per share data)
|
|
|
Three Months Ended
|
|
|
|
|
March 31,
|
|
|
|
|
2024
|
|
|
2023
|
|
|
Net revenue
|
|
$ |
17,993 |
|
|
$ |
22,733 |
|
|
Cost of sales
|
|
|
6,300 |
|
|
|
9,990 |
|
|
Gross profit
|
|
|
11,693 |
|
|
|
12,743 |
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Selling and marketing
|
|
|
6,549 |
|
|
|
12,804 |
|
|
General and administrative
|
|
|
5,442 |
|
|
|
7,177 |
|
|
Research and development
|
|
|
619 |
|
|
|
856 |
|
|
Amortization of intangible assets
|
|
|
1,303 |
|
|
|
1,198 |
|
|
Restructuring costs
|
|
|
244 |
|
|
|
— |
|
|
Gain from contingent consideration
|
|
|
— |
|
|
|
(734 |
) |
|
Total operating expenses
|
|
|
14,157 |
|
|
|
21,301 |
|
|
Loss from operations
|
|
|
(2,464 |
) |
|
|
(8,558 |
) |
|
Other expense, net
|
|
|
(1,195 |
) |
|
|
(1,215 |
) |
|
Gain on derivative warrant liabilities
|
|
|
1,017 |
|
|
|
2,573 |
|
|
Loss before income tax
|
|
|
(2,642 |
) |
|
|
(7,200 |
) |
|
Income tax expense
|
|
|
(245 |
) |
|
|
— |
|
|
Net loss
|
|
$ |
(2,887 |
) |
|
$ |
(7,200 |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted weighted-average common shares outstanding
|
|
|
5,533,555 |
|
|
|
3,726,779 |
|
|
Basic and diluted net loss per common share
|
|
$ |
(0.52 |
) |
|
$ |
(1.93 |
) |
Aytu BioPharma, Inc.
Unaudited Consolidated Balance Sheets
(in thousands, except share data)
|
|
|
March 31,
|
|
|
June 30,
|
|
|
|
|
2024
|
|
|
2023
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
19,760 |
|
|
$ |
22,985 |
|
|
Accounts receivable, net
|
|
|
29,925 |
|
|
|
28,937 |
|
|
Inventories
|
|
|
13,193 |
|
|
|
11,995 |
|
|
Prepaid expenses
|
|
|
7,249 |
|
|
|
8,047 |
|
|
Other current assets
|
|
|
1,003 |
|
|
|
868 |
|
|
Total current assets
|
|
|
71,130 |
|
|
|
72,832 |
|
|
Non-current assets:
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
967 |
|
|
|
1,815 |
|
|
Operating lease right-of-use assets
|
|
|
1,795 |
|
|
|
2,054 |
|
|
Intangible assets, net
|
|
|
54,082 |
|
|
|
58,970 |
|
|
Other non-current assets
|
|
|
889 |
|
|
|
792 |
|
|
Total non-current assets
|
|
|
57,733 |
|
|
|
63,631 |
|
|
Total assets
|
|
$ |
128,863 |
|
|
$ |
136,463 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
10,475 |
|
|
$ |
13,478 |
|
|
Accrued liabilities
|
|
|
44,091 |
|
|
|
46,799 |
|
|
Short-term line of credit
|
|
|
1,581 |
|
|
|
1,563 |
|
|
Current portion of debt
|
|
|
15,135 |
|
|
|
85 |
|
|
Current portion of derivative warrant liabilities
|
|
|
3,261 |
|
|
|
— |
|
|
Other current liabilities
|
|
|
9,146 |
|
|
|
7,090 |
|
|
Total current liabilities
|
|
|
83,689 |
|
|
|
69,015 |
|
|
Non-current liabilities:
|
|
|
|
|
|
|
|
Debt, net of current portion
|
|
|
— |
|
|
|
14,713 |
|
|
Derivative warrant liabilities
|
|
|
8,609 |
|
|
|
6,403 |
|
|
Other non-current liabilities
|
|
|
5,788 |
|
|
|
6,975 |
|
|
Total non-current liabilities
|
|
|
14,397 |
|
|
|
28,091 |
|
|
Stockholders' equity:
|
|
|
|
|
|
|
|
|
|
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding
|
|
|
— |
|
|
|
— |
|
|
Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,909 and 5,517,174 shares issued and outstanding, respectively
|
|
|
1 |
|
|
|
1 |
|
|
Additional paid-in capital
|
|
|
346,132 |
|
|
|
343,485 |
|
|
Accumulated deficit
|
|
|
(315,356 |
) |
|
|
(304,129 |
) |
|
Total stockholders' equity
|
|
|
30,777 |
|
|
|
39,357 |
|
|
Total liabilities and stockholders' equity
|
|
$ |
128,863 |
|
|
$ |
136,463 |
|
Aytu BioPharma, Inc.
Unaudited Reconciliation of Net Loss to Adjusted EBITDA
(in thousands)
|
|
|
For the Three Months Ended March 31, 2024
|
|
| |
|
Rx Business
|
|
|
Consumer Health
|
|
|
Pipeline R&D
|
|
|
Consolidated
|
|
|
Net loss - GAAP
|
|
$ |
(1,876 |
) |
|
$ |
(875 |
) |
|
$ |
(136 |
) |
|
$ |
(2,887 |
) |
|
Depreciation and amortization
|
|
|
1,449 |
|
|
|
385 |
|
|
|
— |
|
|
|
1,834 |
|
|
Stock-based compensation expense
|
|
|
699 |
|
|
|
112 |
|
|
|
— |
|
|
|
811 |
|
|
Other expense, net
|
|
|
1,187 |
|
|
|
8 |
|
|
|
— |
|
|
|
1,195 |
|
|
Gain on derivative warrant liabilities
|
|
|
(1,017 |
) |
|
|
— |
|
|
|
— |
|
|
|
(1,017 |
) |
|
Income tax expense
|
|
|
245 |
|
|
|
— |
|
|
|
— |
|
|
|
245 |
|
|
Restructuring costs
|
|
|
244 |
|
|
|
— |
|
|
|
— |
|
|
|
244 |
|
|
Adjusted EBITDA - non-GAAP
|
|
$ |
931 |
|
|
$ |
(370 |
) |
|
$ |
(136 |
) |
|
$ |
425 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, 2023
|
|
| |
|
Rx Business
|
|
|
Consumer Health
|
|
|
Pipeline R&D
|
|
|
Consolidated
|
|
|
Net loss - GAAP
|
|
$ |
(5,376 |
) |
|
$ |
(1,423 |
) |
|
$ |
(401 |
) |
|
$ |
(7,200 |
) |
|
Depreciation and amortization
|
|
|
1,563 |
|
|
|
280 |
|
|
|
— |
|
|
|
1,843 |
|
|
Stock-based compensation expense
|
|
|
788 |
|
|
|
114 |
|
|
|
13 |
|
|
|
915 |
|
|
Gain from contingent consideration
|
|
|
(345 |
) |
|
|
(389 |
) |
|
|
— |
|
|
|
(734 |
) |
|
Other expense (income), net
|
|
|
1,229 |
|
|
|
(14 |
) |
|
|
— |
|
|
|
1,215 |
|
|
Gain on derivative warrant liabilities
|
|
|
(2,573 |
) |
|
|
— |
|
|
|
— |
|
|
|
(2,573 |
) |
|
Adjusted EBITDA - non-GAAP
|
|
$ |
(4,714 |
) |
|
$ |
(1,432 |
) |
|
$ |
(388 |
) |
|
$ |
(6,534 |
) |
Aytu BioPharma, Inc.
Unaudited Reconciliation of Trailing Twelve-Month Net Income (Loss) to Adjusted EBITDA
(in thousands)
|
Companywide:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the Three Months Ended
|
|
|
|
|
|
| |
|
March 31,
2024
|
|
|
December 31,
2023
|
|
|
September 30,
2023
|
|
|
June 30,
2023
|
|
|
Total TTM
|
|
|
Net loss - GAAP
|
|
$ |
(2,887 |
) |
|
$ |
(220 |
) |
|
$ |
(8,120 |
) |
|
$ |
(2,457 |
) |
|
$ |
(13,684 |
) |
|
Depreciation and amortization
|
|
|
1,834 |
|
|
|
1,899 |
|
|
|
1,941 |
|
|
|
1,836 |
|
|
|
7,510 |
|
|
Stock-based compensation expense
|
|
|
811 |
|
|
|
820 |
|
|
|
930 |
|
|
|
899 |
|
|
|
3,460 |
|
|
Other expense, net
|
|
|
1,195 |
|
|
|
1,179 |
|
|
|
709 |
|
|
|
1,252 |
|
|
|
4,335 |
|
|
(Gain) loss on derivative warrant liabilities
|
|
|
(1,017 |
) |
|
|
577 |
|
|
|
5,907 |
|
|
|
1,374 |
|
|
|
6,841 |
|
|
Income tax expense
|
|
|
245 |
|
|
|
828 |
|
|
|
— |
|
|
|
— |
|
|
|
1,073 |
|
|
Restructuring costs
|
|
|
244 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
244 |
|
|
One-time transactions
|
|
|
— |
|
|
|
— |
|
|
|
851 |
|
|
|
— |
|
|
|
851 |
|
|
Gain from contingent consideration
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(465 |
) |
|
|
(465 |
) |
|
Impairment expense
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,224 |
|
|
|
5,224 |
|
|
Adjusted EBITDA - non-GAAP
|
|
$ |
425 |
|
|
$ |
5,083 |
|
|
$ |
2,218 |
|
|
$ |
7,663 |
|
|
$ |
15,389 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rx Business:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the Three Months Ended
|
|
|
|
|
|
| |
|
March 31,
2024
|
|
|
December 31,
2023
|
|
|
September 30,
2023
|
|
|
June 30,
2023
|
|
|
Total TTM
|
|
|
Net (loss) income - GAAP
|
|
$ |
(1,876 |
) |
|
$ |
667 |
|
|
$ |
(7,321 |
) |
|
$ |
3,677 |
|
|
$ |
(4,853 |
) |
|
Depreciation and amortization
|
|
|
1,449 |
|
|
|
1,510 |
|
|
|
1,554 |
|
|
|
1,562 |
|
|
|
6,075 |
|
|
Stock-based compensation expense
|
|
|
699 |
|
|
|
707 |
|
|
|
725 |
|
|
|
784 |
|
|
|
2,915 |
|
|
Other expense, net
|
|
|
1,187 |
|
|
|
1,170 |
|
|
|
699 |
|
|
|
1,205 |
|
|
|
4,261 |
|
|
(Gain) loss on derivative warrant liabilities
|
|
|
(1,017 |
) |
|
|
577 |
|
|
|
5,907 |
|
|
|
(465 |
) |
|
|
5,002 |
|
|
Income tax expense
|
|
|
245 |
|
|
|
828 |
|
|
|
— |
|
|
|
— |
|
|
|
1,073 |
|
|
Restructuring costs
|
|
|
244 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
244 |
|
|
One-time transactions
|
|
|
— |
|
|
|
— |
|
|
|
851 |
|
|
|
— |
|
|
|
851 |
|
|
Loss from contingent consideration
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,374 |
|
|
|
1,374 |
|
|
Impairment expense
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
130 |
|
|
|
130 |
|
|
Adjusted EBITDA - non-GAAP
|
|
$ |
931 |
|
|
$ |
5,459 |
|
|
$ |
2,415 |
|
|
$ |
8,267 |
|
|
$ |
17,072 |
|
